1. Effects of PNPLA3 I148M on hepatic lipid and very-low-density lipoprotein metabolism in humans
- Author
-
Aarno Palotie, Elias Björnson, Sanni Söderlund, Marja-Riitta Taskinen, Stefano Romeo, Antti Hakkarainen, Samuli Ripatti, Pietari Ripatti, Chris J. Packard, Mari Ainola, Martin Adiels, Marcus Henricsson, Niina Matikainen, Joel T. Rämö, Rosellina Margherita Mancina, Jan Borén, HUS Abdominal Center, Clinicum, CAMM - Research Program for Clinical and Molecular Metabolism, Endokrinologian yksikkö, Institute for Molecular Medicine Finland, Genomics of Neurological and Neuropsychiatric Disorders, Complex Disease Genetics, Helsinki Institute of Life Science HiLIFE, Samuli Olli Ripatti / Principal Investigator, Doctoral Programme in Social Sciences, Centre of Excellence in Complex Disease Genetics, Department of Public Health, Faculty Common Matters (Faculty of Social Sciences), Biostatistics Helsinki, Research Programs Unit, Aarno Palotie / Principal Investigator, INDIVIDRUG - Individualized Drug Therapy, HUS Internal Medicine and Rehabilitation, HUS Medical Imaging Center, and Marja-Riitta Taskinen Research Group
- Subjects
Very low-density lipoprotein ,medicine.medical_specialty ,Apolipoprotein B ,OVERPRODUCTION ,030209 endocrinology & metabolism ,Phospholipase ,Lipoproteins, VLDL ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Internal Medicine ,Medicine ,Humans ,Triglycerides ,fatty liver ,FATTY LIVER-DISEASE ,030304 developmental biology ,0303 health sciences ,biology ,Triglyceride ,business.industry ,Fatty liver ,Lipid metabolism ,Metabolism ,medicine.disease ,Lipid Metabolism ,Lipids ,lipoproteins ,Endocrinology ,chemistry ,Liver ,3121 General medicine, internal medicine and other clinical medicine ,Phospholipases A2, Calcium-Independent ,biology.protein ,lipids (amino acids, peptides, and proteins) ,business ,Acyltransferases ,Lipoprotein - Abstract
Background The phospholipase domain-containing 3 gene (PNPLA3)-148M variant is associated with liver steatosis but its influence on the metabolism of triglyceride-rich lipoproteins remains unclear. Here, we investigated the kinetics of large, triglyceride-rich very-low-density lipoprotein (VLDL), (VLDL1), and smaller VLDL2 in homozygotes for the PNPLA3-148M variant. Methods and results The kinetics of apolipoprotein (apo) B100 (apoB100) and triglyceride in VLDL subfractions were analysed in nine subjects homozygous for PNPLA3-148M and nine subjects homozygous for PNPLA3-148I (controls). Liver fat was >3-fold higher in the 148M subjects. Production rates for apoB100 and triglyceride in VLDL1 did not differ significantly between the two groups. Likewise, production rates for VLDL2-apoB100 and -triglyceride, and fractional clearance rates for both apoB100 and triglyceride in VLDL1 and VLDL2, were not significantly different. Conclusions Despite the higher liver fat content in PNPLA3 148M homozygotes, there was no increase in VLDL production. Equally, VLDL production was maintained at normal levels despite the putative impairment in cytosolic lipid hydrolysis in these subjects.
- Published
- 2021